Clascoterone long-acting injectable - Avidence Therapeutics
Alternative Names: Clascoterone LAI - Avidence TherapeuticsLatest Information Update: 30 Apr 2026
At a glance
- Originator Avidence Therapeutics
- Class Antiacnes; Esters; Pregnenediones; Propionates; Skin disorder therapies; Small molecules
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alopecia
Most Recent Events
- 12 Mar 2026 Preclinical trials in Alopecia in USA (Parenteral)